Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
Castle Biosciences (NASDAQ: CSTL) said its executive management will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, Dec. 2, 2025 at 1:10 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Castle Biosciences (NASDAQ: CSTL) said its executive management will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, Dec. 2, 2025 at 1:10 p.m. ET. A live audio webcast will be available at the company’s investor events page and a replay will be posted after the live broadcast.
Details
News Market Reaction – CSTL
On Nov 11, the day this news came out, CSTL closed 0.66% above the previous close.
Data tracked by StockTitan Argus for the Nov 11 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FRIENDSWOOD, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, Dec. 2, 2025, at 1:10 p.m. Eastern time.
A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.
We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Instagram, Facebook and X.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.